CTS Corporation Q4 Earnings Exceed Expectations

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 6 days ago

0mins

CTS+0.95%

Should l Buy CTS?

Source: seekingalpha

Strong Earnings Performance: CTS Corporation reported a Q4 non-GAAP EPS of $0.62, beating expectations by $0.02, which reflects the company's ongoing profitability enhancement and bolsters investor confidence.
Significant Revenue Growth: The company achieved Q4 revenue of $137.27 million, an 8.5% year-over-year increase, surpassing expectations by $1.41 million, indicating CTS's robust performance amid recovering market demand and suggesting future growth potential.
Margin Improvement: The adjusted gross margin rose to 39.1%, up 150 basis points from 37.6% in Q4 2024, demonstrating positive progress in cost control and pricing strategies, which will help enhance overall profitability.
Optimistic 2026 Outlook: CTS expects full-year 2026 sales to range between $550 million and $580 million, with adjusted diluted EPS projected at $2.30 to $2.45, both exceeding market consensus, showcasing the company's confidence in future performance and competitive positioning.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CTS?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on CTS

About CTS

CTS Corporation is a global manufacturer of sensors, connectivity components, and actuators. The Company designs, manufactures, and sells a broad line of sensors, connectivity components, and actuators primarily to original equipment manufacturers (OEMs), suppliers for the aerospace and defense, industrial, medical, and transportation markets, and the United States Government. The Company’s devices are categorized by their ability to Sense, Connect or Move. Sense products provide vital inputs to electronic systems. Connect products allow systems to function in synchronization with other systems. Move products ensure the required movements are effectively and accurately executed. Its Sense products include Controls, Pedals, Piezo Sensing Products, Sensors, Switches and Transducers. Its Connect products include EMI/RFI Filters, Capacitors, Frequency Control Products, Resistors and RF filters. The Company’s Move products include Piezo Microactuators and Rotary Actuators.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

CTS Corporation Declares Cash Dividend

4 days agoNewsfilter

Dividend Declaration: CTS Corporation's Board of Directors has declared a cash dividend of $0.04 per share, scheduled for payment on April 24, 2026, to shareholders of record as of March 27, 2025, demonstrating the company's commitment to shareholder returns.
Shareholder Return Strategy: This dividend reflects CTS's strong cash flow and profitability, aimed at boosting investor confidence and attracting more long-term investors to the stock.
Market Positioning: As a leading manufacturer of sensors, actuators, and electronic components, CTS serves multiple markets including aerospace/defense, industrial, medical, and transportation, showcasing its diversified business model and market adaptability.
Global Operations: With manufacturing capabilities in North America, Europe, and Asia, CTS is well-positioned to meet global customer demands, further solidifying its leadership in technological innovation and market competition.

CTS Corporation Reports Strong Q4 2025 Earnings and 2026 Outlook

6 days agoseekingalpha

Significant Revenue Growth: CTS Corporation reported fourth quarter sales of $137 million, reflecting a 9% year-over-year increase, with diversified market sales growing by 16%, demonstrating the successful implementation of the company's diversification strategy and strong market demand.
Strong Medical Market Performance: The medical market saw a 41% year-over-year sales increase, highlighting robust growth momentum in therapeutic applications, which further solidifies CTS's market position in the healthcare sector.
Margin Improvement: The adjusted gross margin for the fourth quarter reached 39.1%, up 150 basis points from the prior year, primarily driven by operational efficiencies and an improved market mix, enhancing the company's profitability.
Optimistic 2026 Outlook: Management anticipates sales in the range of $550 million to $580 million for 2026, with adjusted EPS expected between $2.30 and $2.45, reflecting confidence in future market demand and ongoing product innovation.